A phase 1b/2 open-label, ascending single and repeat dose clinical trial designed to evaluate the safety of light-activated Au-011 for the treatment of subjects with small to medium (2.0 mm – 3.4 mm thickness) primary choroidal melanoma

Protocol: 
AAAR2880
Phase: 
I

A phase 1b/2 open-label, ascending single and repeat dose clinical trial designed to evaluate the safety of light-activated Au-011 for the treatment of subjects with small to medium (2.0 mm – 3.4 mm thickness) primary choroidal melanoma

Are you Eligible? (Inclusion Criteria)

Inclusion:
-Be at least 18 years of age
-Have clinically diagnosed primary CM, with no known metastatic disease, ≥
2.0 mm and ≤ 3.4 mm in height, and longest basal diameter ≤ 16 mm.
-. Have primary CM with documented tumor growth on B-scan and/or fundus
photos, OR have primary CM with presence of subretinal fluid by OCT, AND at
least one of the following:
a. Overlying orange pigment (lipofuscin) on fundus photos
b. Vision loss
c. Flashes or floaters

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States